A new partnership between PrecisionLife and Sano Genetics will help advance researchers’ understanding of the drivers of long COVID, identifying at-risk patients and potential drug targets.
PRESS RELEASE
OXFORD, UK May 11, 2022
News
Cambridge, England, May 4th, 2022 – Amphista Therapeutics, a global leader in the discovery and development of next generation targeted protein degradation (TPD) therapeutics, today announced a strategic collaboration with Merck Healthcare, a division of Merck. Under the terms of the agreement, Merck and Amphista will work collaboratively to discover and develop small molecule protein degraders for an initial three targets in oncology and immunology indications.
AMSBIO announce the launch of its StemFit Purotein® range of high purity, high activity recombinant proteins for cell therapy applications.
Continued expansion of cell therapy applications across healthcare and the life sciences is driving a rapidly increasing need for clinically applicable ancillary materials. A key requirement is for recombinant proteins, such as growth factors and cytokines. This demand for clinically applicable recombinant proteins places stringent requirements on product quality, lot-to-lot consistency, and compliance with all relevant laws and regulations.
03 May 2022, Cambridge, UK: STORM Therapeutics, the biotechnology company focused on the discovery of small molecule therapies targeting RNA epigenetic mechanisms, today announces that it has been awarded a Biomedical Catalyst grant by Innovate UK to research and develop new drugs directed against a unique SARS-CoV2 protein utilizing STORM’s proprietary RNA epigenetic platform.
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF
AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT ATTD MEETING
Leading global drug development consultancy Boyds has appointed experienced clinical researcher Caroline Corbett as Director of Clinical Operations to support the team’s continued growth and the rising demand for its specialist clinical trial expertise.
As Director of Clinical Operations at Boyds, Caroline will support Dr Karen O’Hanlon, Vice President of Clinical Operations, with the ongoing growth and development of the clinical operations team and service offering.
Cambridge Innovation Capital (CIC), the venture capital investor focused on building world-leading deeptech and life sciences businesses connected with the Cambridge ecosystem, has raised £225 million ($300 million) for its oversubscribed second fund (Fund II).
Cambridge, UK 25th April 2022– EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the appointment of Paul Beastall as Chair of the Board of Directors. Paul was previously a Non-Executive Director at Evonetix, having joined the Board in 2020. His new appointment to Chair will see him take a more involved role in guiding product development strategy. This announcement follows the Company’s recent patent grant for technology enabling thermally-controlled DNA synthesis.
Marks & Clerk are delighted to announce that Associates Graham McGlashan and Erik Rõuk will be attending the 7th International XR Conference, taking place in Lisbon next month.
The event is taking place in partnership with The Manchester Metropolitan University, ISCTE - Instituto Universitario de Lisboa and the International Association of Immersive Technology Innovation.